Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity.

The emerging role of the transient receptor potential cation channel isotype 6 (TRPC6) as a central contributor to various pathological processes affecting podocytes has generated interest in the development of therapeutics to modulate its function. Recent insights into the regulation of TRPC6 have revealed PKG as a potent negative modulator of TRPC6 conductance and associated signaling via its phosphorylation at two highly conserved amino acid residues: Thr(69)/Thr(70) (Thr(69) in mice and Thr(70) in humans) and Ser(321)/Ser(322) (Ser(321) in mice and Ser(322) in humans). Here, we tested the role of PKG in modulating TRPC6-dependent responses in primary and conditionally immortalized mouse podocytes. TRPC6 was phosphorylated at Thr(69) in nonstimulated podocytes, but this declined upon ANG II stimulation or overexpression of constitutively active calcineurin phosphatase. ANG II induced podocyte motility in an in vitro wound assay, and this was reduced 30-60% in cells overexpressing a phosphomimetic mutant TRPC6 (TRPC6T70E/S322E) or activated PKG (P < 0.05). Pretreatment of podocytes with the PKG agonists S-nitroso-N-acetyl-dl-penicillamine (nitric oxide donor), 8-bromo-cGMP, Bay 41-2772 (soluble guanylate cyclase activator), or phosphodiesterase 5 (PDE5) inhibitor 4-{[3',4'-(methylenedioxy)benzyl]amino}[7]-6-methoxyquinazoline attenuated ANG II-induced Thr(69) dephosphorylation and also inhibited TRPC6-dependent podocyte motility by 30-60%. These data reveal that PKG activation strategies, including PDE5 inhibition, ameliorate ANG II-induced podocyte dysmotility by targeting TRPC6 in podocytes, highlighting the potential therapeutic utility of these approaches to treat hyperactive TRPC6-dependent glomerular disease.

[1]  D. Kass,et al.  Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy , 2014, Proceedings of the National Academy of Sciences.

[2]  D. Kass,et al.  Hyperactive Adverse Mechanical Stress Responses in Dystrophic Heart Are Coupled to Transient Receptor Potential Canonical 6 and Blocked by cGMP–Protein Kinase G Modulation , 2014, Circulation research.

[3]  L. Rosivall,et al.  Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  K. Connelly,et al.  eNOS deficiency predisposes podocytes to injury in diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[5]  Hong Zhang,et al.  Tacrolimus Improves the Proteinuria Remission in Patients with Refractory IgA Nephropathy , 2012, American Journal of Nephrology.

[6]  C. Loddenkemper,et al.  VEGF regulates TRPC6 channels in podocytes. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  W. Kuebler,et al.  Novel pharmacological TRPC inhibitors block hypoxia-induced vasoconstriction. , 2012, Cell calcium.

[8]  C. Antignac,et al.  Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. , 2011, The Journal of clinical investigation.

[9]  R. D. de Boer,et al.  Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. , 2011, The American journal of pathology.

[10]  H. Abboud,et al.  Abundance of TRPC6 protein in glomerular mesangial cells is decreased by ROS and PKC in diabetes. , 2011, American journal of physiology. Cell physiology.

[11]  E. Finch,et al.  TRPC6 enhances angiotensin II-induced albuminuria. , 2011, Journal of the American Society of Nephrology : JASN.

[12]  S. Hatakeyama,et al.  Inhibition of podocyte FAK protects against proteinuria and foot process effacement. , 2010, Journal of the American Society of Nephrology : JASN.

[13]  K. Nakao,et al.  Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-A Signaling in the Heart , 2010, Circulation Research.

[14]  Yizheng Wang,et al.  Targeting TRPC6 channels in oesophageal carcinoma growth , 2010, Expert opinion on therapeutic targets.

[15]  D. Kass,et al.  Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. , 2010, Journal of molecular and cellular cardiology.

[16]  M. Nishida,et al.  Phosphorylation of TRPC6 Channels at Thr69 Is Required for Anti-hypertrophic Effects of Phosphodiesterase 5 Inhibition* , 2010, The Journal of Biological Chemistry.

[17]  N. Zhong,et al.  Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. , 2010, American journal of physiology. Cell physiology.

[18]  B. Hantash,et al.  Calcineurin activation by slow calcium release from intracellular stores suppresses protein kinase C regulation of L-type calcium channels in L6 cells. , 2009, Cell calcium.

[19]  H. Pavenstädt,et al.  Mechanisms of angiotensin II signaling on cytoskeleton of podocytes , 2008, Journal of Molecular Medicine.

[20]  Y. Mori,et al.  Nitric oxide–cGMP–protein kinase G pathway negatively regulates vascular transient receptor potential channel TRPC6 , 2008, The Journal of physiology.

[21]  Kwanghee Kim,et al.  The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A , 2008, Nature Medicine.

[22]  R. Iyengar,et al.  HIV-1 Nef Disrupts the Podocyte Actin Cytoskeleton by Interacting with Diaphanous Interacting Protein* , 2008, Journal of Biological Chemistry.

[23]  M. Pericak-Vance,et al.  A Mutation in the TRPC 6 Cation Channel Causes Familial Focal Segmental Glomerulosclerosis , 2008 .

[24]  M. Gannon,et al.  Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. , 2007, The American journal of pathology.

[25]  C. Montell,et al.  Integration of phosphoinositide- and calmodulin-mediated regulation of TRPC6. , 2007, Molecular cell.

[26]  D. Ingber,et al.  α-Actinin-4 Is Required for Normal Podocyte Adhesion* , 2007, Journal of Biological Chemistry.

[27]  M. Rastaldi,et al.  Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[28]  X. Yao.  TRPC, cGMP-dependent protein kinases and cytosolic Ca2+. , 2007, Handbook of experimental pharmacology.

[29]  R. Zoraghi,et al.  Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. , 2007, Frontiers in bioscience : a journal and virtual library.

[30]  J. Stȩpiński,et al.  Regulation of cGMP synthesis in cultured podocytes by vasoactive hormones. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[31]  John McAnally,et al.  TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. , 2006, The Journal of clinical investigation.

[32]  M. Nishida,et al.  TRPC3 and TRPC6 are essential for angiotensin II‐induced cardiac hypertrophy , 2006, The EMBO journal.

[33]  Yasuhiko Tomino,et al.  Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling , 2006, Nature Cell Biology.

[34]  F. Hofmann,et al.  Function of cGMP-dependent protein kinases as revealed by gene deletion. , 2006, Physiological reviews.

[35]  J. Kim,et al.  Activation of M1 Muscarinic Acetylcholine Receptors Stimulates the Formation of a Multiprotein Complex Centered on TRPC6 Channels* , 2005, Journal of Biological Chemistry.

[36]  M. Pericak-Vance,et al.  A Mutation in the TRPC6 Cation Channel Causes Familial Focal Segmental Glomerulosclerosis , 2005, Science.

[37]  S. Gambaryan,et al.  Immunolocalization of soluble guanylyl cyclase subunits in rat kidney , 2005, Histochemistry and Cell Biology.

[38]  T. Lincoln,et al.  Regulation of cGMP-dependent Protein Kinase Expression by Soluble Guanylyl Cyclase in Vascular Smooth Muscle Cells* , 2004, Journal of Biological Chemistry.

[39]  I. Fantozzi,et al.  Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Y. Tomino,et al.  Podocyte Migration during Nephrotic Syndrome Requires a Coordinated Interplay between Cathepsin L and α3 Integrin* , 2004, Journal of Biological Chemistry.

[41]  D. Rodríguez‐Puyol,et al.  Differential relaxing responses to particulate or soluble guanylyl cyclase activation on endothelial cells: a mechanism dependent on PKG-I alpha activation by NO/cGMP. , 2003, American journal of physiology. Cell physiology.

[42]  J. Kotera,et al.  Phosphorylation of Isolated Human Phosphodiesterase-5 Regulatory Domain Induces an Apparent Conformational Change and Increases cGMP Binding Affinity* , 2002, The Journal of Biological Chemistry.

[43]  M. Marrero,et al.  Angiotensin II stimulates calcineurin activity in proximal tubule epithelia through AT-1 receptor-mediated tyrosine phosphorylation of the PLC-gamma1 isoform. , 2002, Journal of the American Society of Nephrology : JASN.

[44]  H. Nishimatsu,et al.  Angiotensin II Induces Myocyte Enhancer Factor 2- and Calcineurin/Nuclear Factor of Activated T Cell-Dependent Transcriptional Activation in Vascular Myocytes , 2002, Circulation research.

[45]  M. Marrero,et al.  Angiotensin II Stimulates Calcineurin Activity in Proximal Tubule Epithelia through AT-1 Receptor–Mediated Tyrosine Phosphorylation of the PLC- 1 Isoform , 2002 .

[46]  T. Lincoln,et al.  Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. , 2001, Journal of applied physiology.

[47]  M. Giorgi,et al.  Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. , 2001, Biochimica et biophysica acta.

[48]  J. Kaplan,et al.  Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis , 2000, Nature Genetics.

[49]  F. Marumo,et al.  Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments. , 1992, The Journal of clinical investigation.